Factors Linked to Injection Interval Extension in Eyes with Wet Age-Related Macular Degeneration Switched to Brolucizumab-Reference-Cited by-同舟云学术

Factors Linked to Injection Interval Extension in Eyes with Wet Age-Related Macular Degeneration Switched to Brolucizumab

Published:2023-08 Issue:8 Volume:130 Page:795-803
ISSN:0161-6420
Container-title:Ophthalmology
language:en
Short-container-title:Ophthalmology

Author:

MacCumber Mathew W.,Wykoff Charles C.^ORCID,Karcher Helene^ORCID,Adiguzel Eser^ORCID,Sinha Samriddhi Buxy^ORCID,Vishwakarma Saloni,LaPrise Andrew^ORCID,Igwe Franklin,Freitas Rita^ORCID,Ip Michael S.,Zarbin Marco A.^ORCID

Publisher

Elsevier BV

Subject

Ophthalmology

Reference20 articles.

1. Review of neovascular age-related macular degeneration treatment options;Holekamp;Am J Manag Care,2019

2. Antivascular endothelial growth factor agents for wet age-related macular degeneration: an IRIS Registry analysis;MacCumber;Can J Ophthalmol,2023

3. Emerging treatments for wet age-related macular degeneration;Smith;Expert Opin Emerg Drugs,2014

4. Novartis Pharmaceuticals Corporation. Beovu® (brolucizumab) prescribing information. Available at: https://www.novartis.us/sites/www.novartis.us/files/beovu.pdf; 2022. Accessed September 23, 2022.

5. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration;Dugel;Ophthalmology,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-Dose Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration Resistant to Standard-Dose Brolucizumab;Ophthalmology and Therapy;2024-08-30

2. Evaluating photodynamic therapy versus brolucizumab as a second-line treatment for polypoidal choroidal vasculopathy;International Journal of Retina and Vitreous;2024-04-08

3. AI-based support for optical coherence tomography in age-related macular degeneration;International Journal of Retina and Vitreous;2024-04-08

4. The Effect of a Loading Dose Regimen in the Switch to Brolucizumab for Patients with Aflibercept-Resistant nAMD;Journal of Ophthalmology;2024-01-30

5. One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® Registry;Ophthalmology;2023-09